Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 09/27 10:00:00 pm
107.4 USD   +1.03%
09/26 CELGENE CORPORA : - A Challenging yet Rewarding Journey Towards a My..
09/21 CELGENE : Glenmark announces Strategic Development and Global Licens..
09/21 AGIOS PHARMACEU : Appoints Andrew Hirsch as Chief Financial Officer
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
09/26 CELGENE CORPORATION : - A Challenging yet Rewarding Journey Towards a Myeloma Cu..
09/21 CELGENE : Glenmark announces Strategic Development and Global Licensing Agreemen..
09/21 AGIOS PHARMACEUTICALS : Appoints Andrew Hirsch as Chief Financial Officer
09/20 GLENMARK PHARMACEUTICALS : Particle to develop cancer drug
09/16 CELGENE : Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADI..
09/15 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
09/13 CELGENE : First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Import..
09/12 CELGENE CORP /DE/ : Other Events (form 8-K)
09/12 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
09/12 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/27 Allergan Validates Gilead Sciences NASH Pipeline
09/26 Game Plan For The Week - Cramer's Mad Money (9/23/16)
09/22 Reviewing Fortune's 20 'Best Investments' Of The Last Decade
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
09/20 Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target
Advertisement
Financials ($)
Sales 2016 11 080 M
EBIT 2016 5 788 M
Net income 2016 3 415 M
Debt 2016 7 253 M
Yield 2016 -
P/E ratio 2016 26,49
P/E ratio 2017 18,77
EV / Sales 2016 8,09x
EV / Sales 2017 6,66x
Capitalization 82 402 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-11.23%82 402
AMGEN, INC.6.90%129 863
GILEAD SCIENCES, INC.-20.33%106 391
REGENERON PHARMACEUTIC..-25.56%42 552
VERTEX PHARMACEUTICALS..-29.83%21 876
ACTELION LTD21.56%18 591
More Results